Compare Fulford India with VENUS REMEDIES - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FULFORD INDIA vs VENUS REMEDIES - Comparison Results

FULFORD INDIA     Change

Fulford (India) Limited is an Indian affiliate of Schering-Plough Corporation, USA. The company has presence in oncology, virology and cardiovascular segments. In FY06 the topline of the company grew by 15.5% to Rs. 1519 m from Rs. 1279 m in FY05. PA... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FULFORD INDIA VENUS REMEDIES FULFORD INDIA/
VENUS REMEDIES
 
P/E (TTM) x 398.8 -1.0 - View Chart
P/BV x 6.2 0.1 8,739.5% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 FULFORD INDIA   VENUS REMEDIES
EQUITY SHARE DATA
    FULFORD INDIA
Mar-14
VENUS REMEDIES
Mar-18
FULFORD INDIA/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs942126 748.2%   
Low Rs45061 736.5%   
Sales per share (Unadj.) Rs691.4301.8 229.1%  
Earnings per share (Unadj.) Rs11.5-24.9 -46.1%  
Cash flow per share (Unadj.) Rs15.42.5 603.6%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.30-  
Book value per share (Unadj.) Rs380.0293.3 129.6%  
Shares outstanding (eoy) m3.9012.34 31.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.00.3 324.9%   
Avg P/E ratio x60.7-3.8 -1,615.2%  
P/CF ratio (eoy) x45.336.7 123.3%  
Price / Book Value ratio x1.80.3 574.5%  
Dividend payout %17.40-   
Avg Mkt Cap Rs m2,7141,154 235.3%   
No. of employees `0000.40.9 48.0%   
Total wages/salary Rs m505393 128.5%   
Avg. sales/employee Rs Th6,073.04,026.1 150.8%   
Avg. wages/employee Rs Th1,137.4425.0 267.6%   
Avg. net profit/employee Rs Th100.7-331.8 -30.3%   
INCOME DATA
Net Sales Rs m2,6963,724 72.4%  
Other income Rs m12523 557.3%   
Total revenues Rs m2,8223,747 75.3%   
Gross profit Rs m-46395 -11.8%  
Depreciation Rs m15338 4.5%   
Interest Rs m10354 2.7%   
Profit before tax Rs m54-275 -19.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1032 30.4%   
Profit after tax Rs m45-307 -14.6%  
Gross profit margin %-1.710.6 -16.2%  
Effective tax rate %17.7-11.5 -154.0%   
Net profit margin %1.7-8.2 -20.1%  
BALANCE SHEET DATA
Current assets Rs m1,7382,638 65.9%   
Current liabilities Rs m5452,305 23.6%   
Net working cap to sales %44.38.9 495.0%  
Current ratio x3.21.1 278.8%  
Inventory Days Days48135 35.8%  
Debtors Days Days446 9.3%  
Net fixed assets Rs m124,871 0.2%   
Share capital Rs m39123 31.6%   
"Free" reserves Rs m1,4433,496 41.3%   
Net worth Rs m1,4823,619 40.9%   
Long term debt Rs m01,374 0.0%   
Total assets Rs m2,0777,509 27.7%  
Interest coverage x6.70.2 3,011.9%   
Debt to equity ratio x00.4 0.0%  
Sales to assets ratio x1.30.5 261.8%   
Return on assets %2.60.6 413.4%  
Return on equity %3.0-8.5 -35.6%  
Return on capital %4.31.6 272.1%  
Exports to sales %00-   
Imports to sales %24.513.9 176.3%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m659517 127.6%   
Fx inflow Rs m170-   
Fx outflow Rs m673517 130.3%   
Net fx Rs m-656-517 127.0%   
CASH FLOW
From Operations Rs m90514 17.5%  
From Investments Rs m105-123 -85.0%  
From Financial Activity Rs m-14-387 3.6%  
Net Cashflow Rs m1814 4,297.6%  

Share Holding

Indian Promoters % 0.0 32.9 -  
Foreign collaborators % 75.0 0.0 -  
Indian inst/Mut Fund % 3.8 0.2 2,111.1%  
FIIs % 0.1 0.6 17.2%  
ADR/GDR % 0.0 0.0 -  
Free float % 21.2 66.4 31.9%  
Shareholders   4,783 20,121 23.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FULFORD INDIA With:   GLENMARK PHARMA  UNICHEM LAB  WYETH LTD  DIVIS LABORATORIES  ALEMBIC LTD  

Compare FULFORD INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 2301.8% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, VENUS REMEDIES has posted a net profit of Rs 119 m (down 2301.8% YoY). Sales on the other hand came in at Rs 691 m (down 25.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

VENUS REMEDIES Announces Quarterly Results (1QFY19); Net Profit Down 756.1% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, VENUS REMEDIES has posted a net profit of Rs 56 m (down 756.1% YoY). Sales on the other hand came in at Rs 655 m (down 16.2% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FULFORD INDIA SHARE PRICE


Jul 30, 2015 (Close)

TRACK FULFORD INDIA

  • Track your investment in FULFORD INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

FULFORD INDIA 5-YR ANALYSIS

COMPARE FULFORD INDIA WITH

MARKET STATS